Naftopidil inhibits 5-hydroxytryptamine-induced bladder contraction in rats

• Published in: European journal of pharmacology 2013-01, Vol.700 (1-3), p.194-200
• Main Authors: Sakai, Takumi, Kasahara, Ken-ichi, Tomita, Ken-ichi, Ikegaki, Ichiro, Kuriyama, Hiroshi
• Format: Article
• Language: English
• Subjects: 5-HT2A receptor; 5-HT2B receptor; Adrenergic alpha-Antagonists - pharmacology; agonists; Animals; antagonists; bladder; Female; HEK293 Cells; Humans; hyperplasia; In Vitro Techniques; Muscle Contraction - drug effects; Naftopidil; Naphthalenes - pharmacology; patients; pharmacology; phenol; Piperazines - pharmacology; Rats; receptors; Receptors, Serotonin, 5-HT2 - metabolism; serotonin; Serotonin - pharmacology; Serotonin Antagonists - pharmacology; Storage symptoms; Urinary Bladder - drug effects; Urinary Bladder - physiology; α1-adrenoceptor antagonist
• ISSN: 0014-2999; 1879-0712
• DOI: 10.1016/j.ejphar.2012.12.022

Naftopidil is an α1D and α1A subtype-selective α1-adrenoceptor antagonist that has been used to treat lower urinary tract symptoms of benign prostatic hyperplasia. In this study, we investigated the effects of naftopidil on 5-hydroxytryptamine (5-HT)-induced rat bladder contraction (10−8–10−4M). Naftopidil (0.3, 1, and 3μM) inhibited 5-HT-induced bladder contraction in a concentration-dependent manner. On the other hand, other α1-adrenoceptor antagonists, tamsulosin, silodosin or prazosin, did not inhibit 5-HT-induced bladder contraction. The 5-HT-induced bladder contraction was inhibited by both ketanserin and 4-(4-fluoronaphthalen-1-yl)-6-propan-2-ylpyrimidin-2-amine (RS127445), serotonin 5-HT2A and 5-HT2B receptor antagonists, respectively. In addition, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and α-methyl-5-HT, 5-HT2A and 5-HT2 receptor agonists, respectively, induced bladder contraction. The 5-HT-induced bladder contraction was not inhibited by N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-yl-cyclohexanecarboxamide (WAY-100635), [1-[2[(methylsulfonyl)amino]ethyl]-4-piperidinyl]methyl-1-methyl-1H-indole-3-carboxylate (GR113808) or (R)-3-[2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulphonyl]phenol (SB269970), 5-HT1A, 5-HT4 and 5-HT7 receptor antagonists, respectively. Naftopidil inhibited both the 5-HT2A and 5-HT2 receptor agonists-induced bladder contractions. Naftopidil binds to the human 5-HT2A and 5-HT2B receptors with pKi values of 6.55 and 7.82, respectively. These results suggest that naftopidil inhibits 5-HT-induced bladder contraction via blockade of the 5-HT2A and 5-HT2B receptors in rats. Furthermore, 5-HT-induced bladder contraction was enhanced in bladder strips obtained from bladder outlet obstructed rats, with this contraction inhibited by naftopidil. The beneficial effects of naftopidil on storage symptoms such as urinary frequency and nocturia in patients with benign prostatic hyperplasia may be due, in part, to the blockade of the 5-HT2A and 5-HT2B receptors in the bladder.